Trial Profile

An Open Label Pilot Study of Atomoxetine Hydrochloride in Adolescents With Attention Deficit/Hyperactivity Disorder and Comorbid Cannabis Abuse.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atomoxetine (Primary)
Indications Attention-deficit hyperactivity disorder; Substance-related disorders
Focus Therapeutic Use
Acronyms PEACE
Sponsors Eli Lilly and Company

Most Recent Events

18 Aug 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
13 Jan 2010 Actual end date (1 Jul 2009) added as reported by ClinicalTrials.gov.
13 Jan 2010 Actual patient number (7) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com